| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
1 company
Scott M. Pittman is Director, 10% Owner at AURX. Scott M. Pittman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.9M at current prices.
Net of sales, the AURX filings show accumulation of 2,870,000 shares.
Scott M. Pittman has 19 Form 4 filings on record from May 2016 to October 2026, all as Director, 10% Owner at Nuo Therapeutics (AURX), 2016–2026.
The 43 reported transactions were 21 option or other derivative awards, 6 open-market purchases, 5 stock awards and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $1.4M and no sales.
The largest open-market purchase was 825,000 shares of AURX at an average $1.00 on May 5, 2016, about $825K.